NCT07106918View on ClinicalTrials.gov

A Clinical Trial of SIBP-A16 Injection in Healthy Adults

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Respiratory Syncytial Virus (RSV)
Interventions
BIOLOGICAL

SIBP-A16 injection

Single administration via intramuscular or intravenous injection. All participants received a single injection of the corresponding dose.

BIOLOGICAL

Nirsevimab

Single administration via intramuscular.

OTHER

SIBP-A16 buffer solution

Single administration via intramuscular or intravenous injection. All participants received a single injection of the corresponding dose.

All Listed Sponsors
lead

Shanghai Institute Of Biological Products

INDUSTRY